台灣先進智慧股份有限公司
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Drug Repurposing: Utilizing AI technology to discover new therapeutic uses for existing drugs.
2. Novel Target Discovery: Applying ontology-driven AI technology to conduct in-depth analysis and reveal hidden pathogenic mechanisms, thereby discovering potential targets for novel drug development.
3. SaaS Platform: Providing secure cloud access channels that enable R&D teams in enterprises or research institutions to conduct collaborative research 24/7 with the "AI Co-Scientist Agent (comprising seven collaborative specialized agents)," seamlessly integrating the AI R&D assistant directly into daily workflows.
2. Novel Target Discovery: Applying ontology-driven AI technology to conduct in-depth analysis and reveal hidden pathogenic mechanisms, thereby discovering potential targets for novel drug development.
3. SaaS Platform: Providing secure cloud access channels that enable R&D teams in enterprises or research institutions to conduct collaborative research 24/7 with the "AI Co-Scientist Agent (comprising seven collaborative specialized agents)," seamlessly integrating the AI R&D assistant directly into daily workflows.
The content above was translated by Ai
Founded Year
2019
Unified Business No.
82887701
Status
Active
Number of Employees
0
Total Paid-in
Capital
41,999,841 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
台灣先進智慧股份有限公司 operates the brand [amiko ai] and is dedicated to next-generation drug R&D. By combining cutting-edge AI technology with biotechnology domain knowledge, it builds an AI-assisted R&D platform with ontology and large language models (LLMs) at its core, accelerating the biomedical R&D process. Through a multi-agent architecture, seven specialized AI agents work collaboratively to simulate the research thinking and exploration processes of scientists, enhancing the efficiency of drug discovery.
The content above was translated by Ai
